Details of the Drug Reposition

General Information of This Drug (ID: DMLE8T9)

Drug Name
CART30   DMLE8T9
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hodgkin lymphoma DISX2OUL 2B30 Phase 1/2 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas